close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Nanobiotix
Search

Nanobiotix

Suletud

19.38 0.94

Tugev "osta" hinnang

Hinna uuendus 31. dets 2025, 12:54 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.24

Max

19.4

Põhinäitajad

By Trading Economics

Sissetulek

-5.4M

Müük

27M

Kasumimarginaal

-20.208

Töötajad

103

EBITDA

1.1M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+18.92% upside

Turustatistika

By TradingEconomics

Turukapital

933M

Eelmine avamishind

18.44

Eelmine sulgemishind

19.38

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

DJ

Loe

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

DJ

Loe

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

DJ

Loe

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

DJ

Loe

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

DJ

Loe

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

DJ

Loe

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

DJ

Loe

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

DJ

Loe

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

DJ

Loe

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

DJ

Loe

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

DJ

Loe

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

DJ

Loe

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

DJ

Loe

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

DJ

Loe

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

DJ

Loe

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

DJ

Loe

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

DJ

Loe

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

DJ

Loe

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

DJ

Loe

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

DJ

Loe

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

DJ

Loe

31. dets 2025, 13:01 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

DJ

Loe

31. dets 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

DJ

Loe

31. dets 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

DJ

Loe

31. dets 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

DJ

Loe

31. dets 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

DJ

Loe

31. dets 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

DJ

Loe

Nanobiotix Prognoos

Hinnasiht

By TipRanks

18.92% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR  18.92%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
help-icon Live chat